Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lefamulin vs Moxifloxacin in CABP (LEAP 2)
NCT02813694Phase 3Completed
- Sponsor
- Nabriva Therapeutics plc
- Start
- Aug 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of lefamulin in community-acquired bacterial pneumonia (CAP), sponsored by Nabriva Therapeutics plc. Started Aug 2016; status: completed.
02
Drugs
lefamulin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT02813694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02813694.